OTCMKTS:CKPT
Checkpoint Therapeutics, Inc. Stock News
$1.58
+0.100 (+6.76%)
At Close: May 03, 2024
Checkpoint Therapeutics stock plunges on FDA setback
12:22pm, Monday, 18'th Dec 2023
Checkpoint Therapeutics (NASDAQ:CKPT) Inc shares plummeted 48% to $1.72 in midday trading on Monday after the US Food and Drug Administration (FDA) failed to approve its drug development candidate Cos
Checkpoint Therapeutics slides after US FDA declines cancer therapy approval
08:43am, Monday, 18'th Dec 2023
Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration had declined to approve its experimental therapy to treat a form of skin cancer following an inspection at a contract manuf
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
12:26pm, Monday, 11'th Dec 2023
Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
02:48pm, Wednesday, 06'th Dec 2023
Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as thei
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
08:30am, Thursday, 21'st Sep 2023
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that J
Checkpoint: PDUFA Date Catalyst Makes This A Must Watch
07:01pm, Tuesday, 01'st Aug 2023
A PDUFA date of January 3, 2024 has been established by which FDA will decide upon by then whether or not cosibelimab should be approved for the treatment of cSCC. It is said that the cutaneous squamo
Checkpoint Therapeutics: Cosibelimab Data Bolsters Case For Dual-Approval In cSCC
04:19am, Sunday, 30'th Jul 2023
Checkpoint Therapeutics announced updated, longer-term data for cosibelimab from their pivotal trial in locally advanced and metastatic cutaneous squamous cell carcinoma “cSCC”. The data revealed
3 Stocks With 1,000% Upside Potential
10:03am, Sunday, 21'st May 2023
If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potentia
3 Penny Stocks That Could Make You a Millionaire by 2025
04:40pm, Thursday, 11'th May 2023
Penny stocks have had a great start this year, but with uncertainty starting to rear its head again, investors have started to choose safer options instead. Indeed, the underlying businesses of most p
Checkpoint Therapeutics: An Updated Analysis
01:40pm, Tuesday, 10'th Jan 2023
We are checking back in on a small developmental company called Checkpoint Therapeutics, Inc. The company is planning to submit a BLA targeting two indications for its lead product candidate cosibelim
5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts
01:52pm, Tuesday, 27'th Dec 2022
Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, N
Wedbush's Dan Ives offers his bullish outlook on tech in 2023
06:28pm, Monday, 12'th Dec 2022
Dan Ives, Wedbush analyst, joins 'Closing Bell: Overtime' to discuss why he believes there will be a tech rebound.
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
08:30am, Thursday, 22'nd Sep 2022
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that J
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
08:15am, Thursday, 08'th Sep 2022
WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that J
Checkpoint' Cancer Therapy Shows Almost 55% Response Rate In Skin Cancer Patients
09:40am, Thursday, 16'th Jun 2022
Checkpoint Therapeutics Inc (NASDAQ: CKPT) announced positive interim efficacy results from its registration-enabling trial of cosibelimab, in patients with locally advanced cutaneous squamous cell